Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.